National Innovation Platform + Industry Giant Support, InnoMax MedTech Aims to Become the Global Leader in High-End Medical Device CDMO

Innovation has become a consensus in the development of the global medical device industry. However, under the challenges of normalized volume-based procurement, medical insurance cost control, and macroeconomic factors, the domestic medical device industry is generally under pressure. Many medical research and development teams have fallen into the dual dilemma of heavy asset investment and long-cycle risks in the transformation of innovative achievements. Innovative medical device companies focusing on a single product or a few product lines, whose products require long-term clinical verification and follow-up, are facing increasing difficulties.

Medical device CDMO helps companies optimize overall costs, accelerate technology transformation, and shorten product time-to-market by providing services such as innovative product process R&D and manufacturing, registration verification, and batch production, which is becoming a key solution to the current challenges.

However, the medical device CDMO is highly dependent on talent, and resources such as funding, laboratories, and production equipment are indispensable, making the industry threshold relatively high. Precisely because of this,Although this model has matured in Europe and the United States, most domestic companies remain at the component processing stage., only a few companies possess full-process service capabilities from design to production.Fortunately, there are already benchmark companies emerging in the industry today.InnoMax MedTech (hereinafter referred to as "InnoMax MedTech")is a typical representative.

InnoMax MedTech enters the track with the rare combination of a "national innovation platform + industry giant" gene, relying on its industrialization capabilities, as well as the research and development resources of the National Innovation Center for High-Performance Medical Devices (NICC) and Foxconn's manufacturing expertise, to fully build a globally open high-end medical device ecosystem service platform.

The company focuses on fields such as in vitro diagnostics, medical imaging, respiratory assistance, drug delivery devices, wearable medical devices, ophthalmology, and intelligent rehabilitation equipment. With the CDMO model at its core, it provides comprehensive services for high-end medical device companies worldwide, including R&D, manufacturing, and registration (capable of handling precision manufacturing of advanced global medical devices, building a high-end medical device R&D and manufacturing platform, assisting global clients in obtaining multi-national certifications, and offering product development services).

Currently, the company has obtained ISO, NMPA-related system certifications and serves many domestic and international clients who have obtained (including but not limited to) NMPA, CE, FDA and other certifications.

The medical device industry is a high-tech sector that is knowledge-intensive, capital-intensive, and involves the intersection of multiple disciplines, with a long chain of innovation and transformation. Systematic support and one-stop services are crucial forces in driving innovation and transformation.

Partners Visit InnoMax MedTech R&D Headquarters

InnoMax MedTech Chairman ZhiKun Shi pointed out: "Many domestic research and development teams have technical strength but struggle to achieve results. Experts in niche fields alone often cannot independently complete the entire process from R&D, design, to registration and mass production. Building a team and setting up production lines further increase costs and extend timelines, making it easy to fail midway due to insufficient funding. Therefore, we chose to establish InnoMax MedTech to address these pain points while achieving a powerful collaboration between the National Innovation Center and Foxconn, with the hope of thoroughly developing and perfecting the medical device CDMO sector."

Based on this industry understanding, InnoMax MedTech has built a business structure centered on customer needs. By forming a professional R&D design team to deeply engage with customer requirements, they become involved from the project concept stage. They assist customers in organizing design logic, sketching out plans, creating physical models, and follow the optimization process throughout until the customer's product reaches the mass production stage.

After entering the mass production phase, customized support such as automated equipment configuration and mold development is provided. At the same time, an experienced mass production operations team coordinates all aspects, including supply chain management, quality control, and production execution, forming a full-process response capability from R&D to mass production.

The core reason why InnoMax MedTech can solve the domestic CDMO industry's lack of full-process service capabilities lies in its integration of the National Innovation Center resources and its possession of Foxconn genes.

The National Innovation Center, backed by the advanced research institute of the Chinese Academy of Sciences and domestic medical device industry resources, has a strong foundation in industrial R&D. Its capabilities complement the industrialization capacity of InnoMax MedTech. This synergy allows InnoMax MedTech to surpass the R&D boundaries of a single enterprise. When serving clients both domestically and internationally, the R&D strength of the National Innovation Center and the industrialization ability of InnoMax MedTech form a closed loop. Together, they can handle core businesses such as hardware R&D and manufacturing while jointly addressing cross-disciplinary technical challenges, rapidly advancing products from the R&D stage to prototype mass production and global market entry.

As the global manufacturing leader, Foxconn’s extensive global customer network, supply chain system, and advanced manufacturing expertise have infused InnoMax MedTech with a differentiated industrial gene. InnoMax MedTech not only provides core services such as complete R&D and manufacturing of medical devices and product compliance management but also possesses design capabilities that extend to customized workshops for medical devices, fully meeting customers' personalized manufacturing needs.

This resource integration capability enables InnoMax MedTech to cover the full lifecycle needs of clients of different sizes, providing end-to-end empowerment from early-stage R&D, manufacturing to sales, addressing the pain point of limited resources.

The medical device field already has similar mature models; the cooperation between IVD giant Roche and Hitachi has lasted for over four decades. The collaboration goes beyond simple OEM, involving joint development of testing equipment and automated instruments, creating a deeply synergistic industrial ecosystem. However, domestic medical device CDMOs are relatively lagging in this aspect.

Now, InnoMax MedTech is filling this gap with an internationally mature model approach.

At the supply chain level, InnoMax MedTech integrates over 5000 pre-audit qualified suppliers worldwide, covering medical-grade raw materials, core components, and packaging materials, while fully leveraging its capabilities as a leading enterprise in the industry chain.Building on this, InnoMax MedTech incorporates suppliers into its industrial partnership system. Relying on the mature industrial ecosystems of the Greater Bay Area and East China, the company precisely selects high-quality partners to effectively connect dispersed processes such as injection molding, SMT, and machining. This creates a supply chain network covering the entire chain, providing customers with full-process support from core components to complete machines. At the same time, by leveraging ERP/MES systems to achieve end-to-end collaboration in procurement, inventory, and logistics, it not only shortens the procurement cycle but also enables rapid response to urgent orders. InnoMax MedTech established an MES system at its inception, which can provide traceability management for global customers—a crucial feature for medical devices.

InnoMax MedTech R&D Product: Micro Mesh Nebulizer

In the R&D sector, InnoMax MedTech focuses on niche areas such as respiratory assistance and blood glucose management, accumulating long-term and targeted R&D experience.Currently, the company has jointly built laboratories with multiple domestic and international clients, creating a bridge for the transformation of research and development into manufacturing. This accumulation is not a quick process but has been achieved through continuous in-depth work in specific medical scenarios, forming a precise ability to overcome technical difficulties, laying a solid foundation for the transformation from concept to product.

More crucially, the deep integration of advanced precision manufacturing capabilities with quality control systems forms the core support for meeting international standards.

Wang Luyao, General Manager of InnoMax MedTech, pointed out that InnoMax MedTech does not provide fragmented services, but instead adheres to international high standards, integrating quality throughout the entire process to ensure both compliance and product strength.Relying on ISO 13485, international quality management systems, and medical device manufacturing licensing standards, compliance and stability are ensured across all processes from prototype development to mass production. This not only meets the regulatory requirements of multiple countries such as NMPA, FDA, and CE but also guarantees stable product performance through stringent quality control. This system precisely addresses industry pain points where some domestic companies merely achieve "basic compliance," with product shelf life and reliability falling short of overseas top-tier levels, truly aligning with international high-quality control standards. In the second half of this year, InnoMax MedTech is also striving for MDSAP certification. Obtaining this certification signifies that China's medical devices are further breaking through bottlenecks in overseas markets.

It is the comprehensive strength of the entire chain, from R&D to supply chain, to high-end precision manufacturing and quality control, that enables InnoMax MedTech to truly achieve deep empowerment of the medical device industry.

In 2024, going global has become a key strategy for domestic medical device companies. According to QYResearch statistics, the global medical device market size reached $635.8 billion in 2024. It is projected that by 2031, the global medical device market will reach $909.8 billion, with a compound annual growth rate (CAGR) of 5.1% from 2025 to 2031. According to data from the National Medical Products Administration, China's medical device market size was 1.11 trillion yuan in 2024. The overseas market undoubtedly offers broader market space and more growth opportunities, providing strong motivation for domestic companies to expand internationally.

However, the road to going global is not smooth. Systemic barriers formed by regulations and certifications, multi-dimensional restrictions in market access, and the resilience tests of supply chains and service networks remain core challenges that enterprises need to overcome.

As a CDMO enterprise with international genes, InnoMax MedTech is strategically positioned for the global market in the long term.

InnoMax MedTech Points to Global Layout

After three years of foundational strengthening in the early stages, the company is now fully advancing its global layout. It plans to establish pilot incubation platforms in key regions such as Singapore, while simultaneously planning to build overseas CDMO factories and service systems in places like Singapore and Malaysia. This aims to deeply connect with large medical device enterprises in Europe and America. This strategic layout not only leverages geographical advantages to stay close to international markets but also lays the groundwork for serving top-tier global clients by building a team with international communication and technical discussion capabilities.

On the one hand, introducing advanced foreign medical device technologies and products into the Chinese market, and on the other hand, assisting domestic excellent technologies and products to go overseas. Effectively breaking down geographical barriers and standard differences in cross-border cooperation, providing full-process support from technical optimization to market implementation for customers at home and abroad.

More notably, it plans to establish an industrial investment fund with partners to provide targeted empowerment to clients of joint laboratories and high-quality yet financing-constrained medical device companies, addressing the funding pain points of innovative projects.

This business model, which features a global layout, full-chain services, and ecological support, enables InnoMax MedTech to meet clients' compliance and efficiency needs in cross-border cooperation.It can also integrate ecological resources to cover the entire life cycle from R&D, production to market and capital., ultimately achieving the core goal of providing integrated services to every medical device company.

It is reported that InnoMax MedTech will also establish its East China headquarters in Wuxi in the second half of the year to support the surrounding medical device industry ecosystem. From addressing the heavy asset challenges in domestic medical device innovation and transformation, to filling the gaps in local CDMO full-process service capabilities, and further becoming a two-way bridge connecting global markets, InnoMax MedTech is undoubtedly reshaping the industry's value perception of medical device CDMOs.